vs

Side-by-side financial comparison of Ginkgo Bioworks Holdings, Inc. (DNA) and SANDRIDGE ENERGY INC (SD). Click either name above to swap in a different company.

SANDRIDGE ENERGY INC is the larger business by last-quarter revenue ($39.4M vs $33.4M, roughly 1.2× Ginkgo Bioworks Holdings, Inc.). On growth, SANDRIDGE ENERGY INC posted the faster year-over-year revenue change (1.1% vs -23.8%). SANDRIDGE ENERGY INC produced more free cash flow last quarter ($14.4M vs $-47.7M). Over the past eight quarters, SANDRIDGE ENERGY INC's revenue compounded faster (14.1% CAGR vs -6.2%).

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...

SandRidge Energy, Inc. is a company engaged in hydrocarbon exploration in the Mid-Continent region of the United States. It is organized in Delaware and headquartered in Oklahoma City, Oklahoma.

DNA vs SD — Head-to-Head

Bigger by revenue
SD
SD
1.2× larger
SD
$39.4M
$33.4M
DNA
Growing faster (revenue YoY)
SD
SD
+24.9% gap
SD
1.1%
-23.8%
DNA
More free cash flow
SD
SD
$62.1M more FCF
SD
$14.4M
$-47.7M
DNA
Faster 2-yr revenue CAGR
SD
SD
Annualised
SD
14.1%
-6.2%
DNA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DNA
DNA
SD
SD
Revenue
$33.4M
$39.4M
Net Profit
$21.6M
Gross Margin
Operating Margin
-211.9%
38.5%
Net Margin
54.9%
Revenue YoY
-23.8%
1.1%
Net Profit YoY
23.1%
EPS (diluted)
$-1.41
$0.59

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DNA
DNA
SD
SD
Q4 25
$33.4M
$39.4M
Q3 25
$38.8M
$39.8M
Q2 25
$49.6M
$34.5M
Q1 25
$48.3M
$42.6M
Q4 24
$43.8M
$39.0M
Q3 24
$89.0M
$30.1M
Q2 24
$56.2M
$26.0M
Q1 24
$37.9M
$30.3M
Net Profit
DNA
DNA
SD
SD
Q4 25
$21.6M
Q3 25
$-80.8M
$16.0M
Q2 25
$-60.3M
$19.6M
Q1 25
$-91.0M
$13.0M
Q4 24
$17.6M
Q3 24
$-56.4M
$25.5M
Q2 24
$-217.2M
$8.8M
Q1 24
$-165.9M
$11.1M
Operating Margin
DNA
DNA
SD
SD
Q4 25
-211.9%
38.5%
Q3 25
-231.8%
37.8%
Q2 25
-132.1%
53.7%
Q1 25
-184.1%
28.6%
Q4 24
-236.3%
25.9%
Q3 24
-62.0%
28.3%
Q2 24
-396.7%
23.9%
Q1 24
-469.1%
27.8%
Net Margin
DNA
DNA
SD
SD
Q4 25
54.9%
Q3 25
-207.9%
40.1%
Q2 25
-121.6%
56.6%
Q1 25
-188.2%
30.6%
Q4 24
45.1%
Q3 24
-63.3%
84.8%
Q2 24
-386.4%
33.9%
Q1 24
-437.3%
36.7%
EPS (diluted)
DNA
DNA
SD
SD
Q4 25
$-1.41
$0.59
Q3 25
$-1.45
$0.43
Q2 25
$-1.10
$0.53
Q1 25
$-1.68
$0.35
Q4 24
$-1.91
$0.46
Q3 24
$-1.08
$0.69
Q2 24
$-4.23
$0.24
Q1 24
$-3.32
$0.30

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DNA
DNA
SD
SD
Cash + ST InvestmentsLiquidity on hand
$422.6M
$111.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$508.6M
$510.9M
Total Assets
$1.1B
$644.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DNA
DNA
SD
SD
Q4 25
$422.6M
$111.0M
Q3 25
$495.5M
$101.2M
Q2 25
$559.4M
$102.8M
Q1 25
$325.3M
$99.7M
Q4 24
$561.6M
$98.1M
Q3 24
$616.2M
$92.7M
Q2 24
$730.4M
$209.9M
Q1 24
$840.4M
$207.0M
Stockholders' Equity
DNA
DNA
SD
SD
Q4 25
$508.6M
$510.9M
Q3 25
$559.8M
$492.4M
Q2 25
$613.0M
$480.2M
Q1 25
$647.4M
$464.9M
Q4 24
$716.1M
$460.5M
Q3 24
$797.9M
$446.8M
Q2 24
$833.1M
$424.8M
Q1 24
$987.3M
$419.7M
Total Assets
DNA
DNA
SD
SD
Q4 25
$1.1B
$644.0M
Q3 25
$1.2B
$619.0M
Q2 25
$1.2B
$602.3M
Q1 25
$1.3B
$588.3M
Q4 24
$1.4B
$581.5M
Q3 24
$1.5B
$565.2M
Q2 24
$1.6B
$529.6M
Q1 24
$1.6B
$527.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DNA
DNA
SD
SD
Operating Cash FlowLast quarter
$-47.7M
$31.7M
Free Cash FlowOCF − Capex
$-47.7M
$14.4M
FCF MarginFCF / Revenue
-142.8%
36.6%
Capex IntensityCapex / Revenue
0.0%
43.8%
Cash ConversionOCF / Net Profit
1.46×
TTM Free Cash FlowTrailing 4 quarters
$41.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DNA
DNA
SD
SD
Q4 25
$-47.7M
$31.7M
Q3 25
$-31.6M
$25.3M
Q2 25
$-40.3M
$22.9M
Q1 25
$-51.5M
$20.3M
Q4 24
$-42.4M
$26.0M
Q3 24
$-103.5M
$20.8M
Q2 24
$-84.4M
$11.4M
Q1 24
$-89.3M
$15.7M
Free Cash Flow
DNA
DNA
SD
SD
Q4 25
$-47.7M
$14.4M
Q3 25
$5.9M
Q2 25
$-40.3M
$7.3M
Q1 25
$-59.1M
$13.9M
Q4 24
$-56.1M
$13.2M
Q3 24
$-118.6M
$10.8M
Q2 24
$-111.4M
$9.0M
Q1 24
$-96.0M
$14.6M
FCF Margin
DNA
DNA
SD
SD
Q4 25
-142.8%
36.6%
Q3 25
14.9%
Q2 25
-81.2%
21.0%
Q1 25
-122.4%
32.7%
Q4 24
-128.0%
33.8%
Q3 24
-133.2%
36.1%
Q2 24
-198.2%
34.5%
Q1 24
-252.9%
48.1%
Capex Intensity
DNA
DNA
SD
SD
Q4 25
0.0%
43.8%
Q3 25
0.0%
48.6%
Q2 25
0.1%
45.2%
Q1 25
15.8%
15.0%
Q4 24
31.3%
32.9%
Q3 24
16.9%
33.3%
Q2 24
48.1%
9.4%
Q1 24
17.7%
3.7%
Cash Conversion
DNA
DNA
SD
SD
Q4 25
1.46×
Q3 25
1.58×
Q2 25
1.17×
Q1 25
1.56×
Q4 24
1.48×
Q3 24
0.82×
Q2 24
1.30×
Q1 24
1.41×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DNA
DNA

Cell Engineering Segment$26.0M78%
Other$7.4M22%

SD
SD

Oil Reserves$19.0M48%
Natural Gas Reserves$11.6M30%
Natural Gas Liquids Reserves$8.7M22%

Related Comparisons